Understanding of leukemic stem cells and their clinical implications

被引：58

作者：

Wang, Xuefei ^{[1
,2
]}

Huang, Shile ^{[3
]}

Chen, Ji-Long ^{[1
,2
,4
]}

机构：

[1] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China

[2] Univ Chinese Acad Sci, Beijing, Peoples R China

[3] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71105 USA

[4] Fujian Agr & Forestry Univ, Coll Anim Sci, Fuzhou, Peoples R China

来源：

MOLECULAR CANCER | 2017年 / 16卷

关键词：

Cancer stem cell; Leukemia; Leukemic stem cell; Surface markers; BM niche; ncRNAs; Clinical implications; ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNA; ACUTE MYELOGENOUS LEUKEMIA; ABILITY IN-VITRO; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEDGEHOG PATHWAY ACTIVATION; METHYLTRANSFERASE GENE EZH2; AKT INHIBITOR PERIFOSINE; LECTIN-LIKE MOLECULE-1; SELF-RENEWAL CAPACITY;

D O I：

10.1186/s12943-016-0574-7

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Since leukemic stem cells (LSCs) or cancer stem cells (CSCs) were found in acute myeloid leukemia (AML) in 1997, extensive studies have been contributed to identification and characterization of such cell populations in various tissues. LSCs are now generally recognized as a heterogeneous cell population that possesses the capacities of self-renewal, proliferation and differentiation. It has been shown that LSCs are regulated by critical surface antigens, microenvironment, intrinsic signaling pathways, and novel molecules such as some ncRNAs. To date, significant progress has been made in understanding of LSCs, leading to the development of numerous LSCs-targeted therapies. Moreover, various novel therapeutic agents targeting LSCs are undergoing clinical trials. Here, we review current knowledge of LSCs, and discuss the potential therapies and their challenges that are being tested in clinical trials for evaluation of their effects on leukemias.

引用

页数：10

共 193 条

[1] Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies [J].

Abdel-Wahab, Omar ;

Mullally, Ann ;

Hedvat, Cyrus ;

Garcia-Manero, Guillermo ;

Patel, Jay ;

Wadleigh, Martha ;

Malinge, Sebastien ;

Yao, JinJuan ;

Kilpivaara, Outi ;

Bhat, Rukhmi ;

Huberman, Kety ;

Thomas, Sabrena ;

Dolgalev, Igor ;

Heguy, Adriana ;

Paietta, Elisabeth ;

Le Beau, Michelle M. ;

Beran, Miloslav ;

Tallman, Martin S. ;

Ebert, Benjamin L. ;

Kantarjian, Hagop M. ;

Stone, Richard M. ;

Gilliland, D. Gary ;

Crispino, John D. ;

Levine, Ross L. .

BLOOD, 2009, 114 (01) :144-147

[2] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[3] Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) [J].

Amadori, Sergio ;

Stasi, Roberto ;

Martelli, Alberto M. ;

Venditti, Adriano ;

Meloni, Giovanna ;

Pane, Fabrizio ;

Martinelli, Giovanni ;

Lunghi, Monia ;

Pagano, Livio ;

Cilloni, Daniela ;

Rossetti, Elena ;

Di Raimondo, Francesco ;

Fozza, Claudio ;

Annino, Luciana ;

Chiarini, Francesca ;

Ricci, Francesca ;

Ammatuna, Emanuele ;

La Sala, Edoardo ;

Fazi, Paola ;

Vignetti, Marco .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (02) :205-212

[4]

[Anonymous], ONCOTARGET

[5] Chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET, 2015, 385 (9976) :1447-1459

[6] Selective killing of candidate AML stem cells by antibody targeting of IL1RAP [J].

Askmyr, Maria ;

Agerstam, Helena ;

Hansen, Nils ;

Gordon, Sandra ;

Arvanitakis, Alexandros ;

Rissler, Marianne ;

Juliusson, Gunnar ;

Richter, Johan ;

Jaras, Marcus ;

Fioretos, Thoas .

BLOOD, 2013, 121 (18) :3709-3713

[7] Long non-coding RNAs and control of gene expression in the immune system [J].

Atianand, Maninjay K. ;

Fitzgerald, Katherine A. .

TRENDS IN MOLECULAR MEDICINE, 2014, 20 (11) :623-631

[8] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [J].

Attar, Eyal C. ;

Amrein, Philip C. ;

Fraser, James W. ;

Fathi, Amir T. ;

McAfee, Steven ;

Wadleigh, Martha ;

DeAngelo, Daniel J. ;

Steensma, David P. ;

Stone, Richard M. ;

Foster, Julia ;

Neuberg, Donna ;

Ballen, Karen K. .

LEUKEMIA RESEARCH, 2013, 37 (09) :1016-1020

[9] C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia [J].

Bakker, ABH ;

van den Oudenrijn, S ;

Bakker, AQ ;

Feller, N ;

van Meijer, M ;

Bia, JA ;

Jongeneelen, MAC ;

Visser, TJ ;

Bijl, N ;

Geuijen, CAW ;

Marissen, WE ;

Radosevic, K ;

Throsby, M ;

Schuurhuis, GJ ;

Ossenkoppele, GJ ;

de Kruif, J ;

Goudsmit, J ;

Kiuisbeek, AM .

CANCER RESEARCH, 2004, 64 (22) :8443-8450

[10] Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice [J].

Bhatia, M ;

Wang, JCY ;

Kapp, U ;

Bonnet, D ;

Dick, JE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5320-5325

← 1 2 3 4 5 6 7 8 9 10 →